Shots:
- AstraZeneca has reported the global P-III (I CAN/ALXN1210-IgAN-320) trial assessing Ultomiris (IV) vs PBO in ~510 adults with IgAN who are at risk of disease progression
- Trial showed a 46.6% reduction in 24-hr. UPCR from baseline at 34wks. vs 5.6% with PBO, as early as Wk. 10 & sustained through 34wks. The results were consistent across all subgroups. Data were presented at ERA’26
- Ultomiris is a long-acting C5 complement inhibitor that delivers immediate, complete, & sustained inhibition by blocking the C5 protein in the terminal complement cascade, preventing overactivation that can cause the immune system to attack healthy cells
Ref: AstraZeneca | Image: AstraZeneca | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
